Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for PRME

Stock NamePrime Medicine, Inc. Common Stock
TickerPRME(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS74168J1016

Show aggregate PRME holdings

News associated with PRME

Prime Medicine, Inc. (NYSE:PRME) Receives $8.92 Consensus Target Price from Analysts
Prime Medicine, Inc. (NYSE:PRME – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eight research firms that are presently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong […] - 2025-09-15 02:30:21
Prime Medicine (NASDAQ:PRME) Stock Price Down 3.7% on Analyst Downgrade
Prime Medicine, Inc. (NASDAQ:PRME – Get Free Report)’s share price was down 3.7% on Tuesday after Wall Street Zen downgraded the stock from a hold rating to a sell rating. The stock traded as low as $3.09 and last traded at $3.12. Approximately 3,103,838 shares traded hands during mid-day trading, a decline of 4% from […] - 2025-09-04 02:20:47
Prime Medicine (NYSE:PRME) Shares Gap Up on Insider Buying Activity
Prime Medicine, Inc. (NYSE:PRME – Get Free Report)’s share price gapped up prior to trading on Monday after an insider bought additional shares in the company. The stock had previously closed at $4.04, but opened at $4.35. Prime Medicine shares last traded at $4.56, with a volume of 960,713 shares changing hands. Specifically, major shareholder […] - 2025-08-05 02:22:50
Prime Medicine, Inc. (NYSE:PRME) Given Average Recommendation of “Moderate Buy” by Brokerages
Prime Medicine, Inc. (NYSE:PRME – Get Free Report) has received an average rating of “Moderate Buy” from the eight analysts that are currently covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating on the […] - 2025-07-24 05:11:01
Investors Purchase High Volume of Prime Medicine Call Options (NYSE:PRME)
Prime Medicine, Inc. (NYSE:PRME – Get Free Report) was the recipient of unusually large options trading activity on Monday. Stock traders purchased 3,683 call options on the stock. This is an increase of approximately 361% compared to the average volume of 799 call options. Insider Transactions at Prime Medicine In other news, major shareholder David […] - 2025-07-08 02:19:51
Bank of America Corp DE Cuts Stock Holdings in Prime Medicine, Inc. (NYSE:PRME)
Bank of America Corp DE trimmed its holdings in shares of Prime Medicine, Inc. (NYSE:PRME – Free Report) by 11.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 430,613 shares of the company’s stock after selling 54,512 shares during the period. […] - 2025-06-06 04:37:00
BNP Paribas Financial Markets Takes Position in Prime Medicine, Inc. (NYSE:PRME)
BNP Paribas Financial Markets bought a new stake in Prime Medicine, Inc. (NYSE:PRME – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 20,096 shares of the company’s stock, valued at approximately $59,000. Other institutional investors and hedge […] - 2025-06-03 04:58:53
Prime Medicine (NYSE:PRME) Receives “Neutral” Rating from Citigroup
Prime Medicine (NYSE:PRME – Get Free Report)‘s stock had its “neutral” rating restated by equities researchers at Citigroup in a research note issued to investors on Tuesday, Marketbeat.com reports. They presently have a $1.50 price objective on the stock, down from their prior price objective of $10.00. Citigroup’s price target would indicate a potential upside […] - 2025-05-29 02:15:12
JMP Securities Cuts Prime Medicine (NYSE:PRME) Price Target to $6.00
Prime Medicine (NYSE:PRME – Free Report) had its price target trimmed by JMP Securities from $10.00 to $6.00 in a research report released on Tuesday morning,Benzinga reports. The firm currently has a market outperform rating on the stock. PRME has been the topic of a number of other reports. Wall Street Zen raised Prime Medicine […] - 2025-05-23 05:09:02
Chardan Capital Has Lowered Expectations for Prime Medicine (NYSE:PRME) Stock Price
Prime Medicine (NYSE:PRME – Get Free Report) had its price target decreased by stock analysts at Chardan Capital from $16.00 to $12.00 in a report released on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. A number of other research analysts have also recently commented on PRME. StockNews.com raised shares of […] - 2025-05-21 05:14:50
Balyasny Asset Management L.P. Purchases New Holdings in Prime Medicine, Inc. (NYSE:PRME)
Balyasny Asset Management L.P. purchased a new stake in Prime Medicine, Inc. (NYSE:PRME – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 16,342 shares of the company’s stock, valued at approximately $48,000. A number of other hedge funds […] - 2025-05-20 04:42:56
Head to Head Review: Prime Medicine (NYSE:PRME) and BioCryst Pharmaceuticals (NASDAQ:BCRX)
Prime Medicine (NYSE:PRME – Get Free Report) and BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership. Valuation and Earnings This table compares Prime Medicine […] - 2025-05-20 02:46:51
Wells Fargo & Company MN Lowers Holdings in Prime Medicine, Inc. (NYSE:PRME)
Wells Fargo & Company MN trimmed its position in shares of Prime Medicine, Inc. (NYSE:PRME – Free Report) by 43.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 96,181 shares of the company’s stock after selling 75,287 shares during the period. Wells Fargo & Company MN’s holdings in Prime Medicine were worth $281,000 as […] - 2025-05-07 04:24:56
XTX Topco Ltd Makes New Investment in Prime Medicine, Inc. (NYSE:PRME)
XTX Topco Ltd purchased a new position in Prime Medicine, Inc. (NYSE:PRME – Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 14,466 shares of the company’s stock, valued at approximately $42,000. Other hedge funds have also bought and sold shares of the […] - 2025-05-02 05:10:54
Prime Medicine, Inc. (NYSE:PRME) Shares Acquired by Walleye Capital LLC
Walleye Capital LLC increased its position in shares of Prime Medicine, Inc. (NYSE:PRME – Free Report) by 272.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 403,739 shares of the company’s stock after purchasing an additional 295,365 shares […] - 2025-04-21 05:16:56
Prime Medicine, Inc. (NYSE:PRME) Receives $13.38 Consensus Price Target from Analysts
Shares of Prime Medicine, Inc. (NYSE:PRME – Get Free Report) have been given a consensus recommendation of “Buy” by the nine analysts that are covering the company, Marketbeat.com reports. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year […] - 2025-04-18 02:28:53
Critical Review: Prime Medicine (NYSE:PRME) and Pluri (NASDAQ:PLUR)
Pluri (NASDAQ:PLUR – Get Free Report) and Prime Medicine (NYSE:PRME – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings. Risk & Volatility Pluri has a beta of […] - 2025-04-15 02:44:49
Prime Medicine (NYSE:PRME) Receives “Outperform” Rating from Wedbush
Wedbush reaffirmed their outperform rating on shares of Prime Medicine (NYSE:PRME – Free Report) in a research note published on Tuesday,RTT News reports. The firm currently has a $13.00 price target on the stock, up from their prior price target of $12.00. A number of other research firms have also recently commented on PRME. StockNews.com […] - 2025-03-19 04:40:51
Reviewing Prime Medicine (NYSE:PRME) & Bio-Techne (NASDAQ:TECH)
Prime Medicine (NYSE:PRME – Get Free Report) and Bio-Techne (NASDAQ:TECH – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability and risk. Risk & Volatility Prime Medicine has a beta of […] - 2025-02-28 05:00:48
Prime Medicine, Inc. (NYSE:PRME) Receives $13.13 Average Target Price from Brokerages
Prime Medicine, Inc. (NYSE:PRME – Get Free Report) has been assigned an average rating of “Buy” from the ten research firms that are currently covering the stock, MarketBeat reports. Nine analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target […] - 2025-02-27 04:09:13
Prime Medicine (NYSE:PRME) versus Qiagen (NYSE:QGEN) Financial Review
Prime Medicine (NYSE:PRME – Get Free Report) and Qiagen (NYSE:QGEN – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, profitability, institutional ownership and earnings. Insider & Institutional Ownership 70.4% of Prime Medicine shares […] - 2025-02-19 04:12:57
Prime Medicine (NYSE:PRME) Upgraded at StockNews.com
StockNews.com upgraded shares of Prime Medicine (NYSE:PRME – Free Report) to a sell rating in a report released on Tuesday. A number of other equities research analysts have also recently issued reports on PRME. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Prime Medicine in a research note […] - 2025-02-14 06:32:51
Sumitomo Mitsui Trust Group Inc. Sells 100,275 Shares of Prime Medicine, Inc. (NYSE:PRME)
Sumitomo Mitsui Trust Group Inc. lessened its position in shares of Prime Medicine, Inc. (NYSE:PRME – Free Report) by 3.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,090,180 shares of the company’s stock after selling 100,275 shares during the […] - 2025-02-13 08:16:49
China Universal Asset Management Co. Ltd. Buys 4,725 Shares of Prime Medicine, Inc. (NYSE:PRME)
China Universal Asset Management Co. Ltd. grew its stake in shares of Prime Medicine, Inc. (NYSE:PRME – Free Report) by 20.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 27,811 shares of the company’s stock after acquiring an additional 4,725 shares during the quarter. […] - 2025-02-04 07:14:55
Brokerages Set Prime Medicine, Inc. (NYSE:PRME) PT at $13.13
Shares of Prime Medicine, Inc. (NYSE:PRME – Get Free Report) have received a consensus rating of “Buy” from the ten brokerages that are currently covering the firm, MarketBeat Ratings reports. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month […] - 2025-02-04 06:36:56
Prime Medicine (NYSE:PRME) and Windtree Therapeutics (NASDAQ:WINT) Critical Survey
Prime Medicine (NYSE:PRME – Get Free Report) and Windtree Therapeutics (NASDAQ:WINT – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations. Insider & Institutional Ownership 70.4% of Prime […] - 2025-02-04 04:46:59

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) PRME holdings

DateNumber of PRME Shares HeldBase Market Value of PRME SharesLocal Market Value of PRME SharesChange in PRME Shares HeldChange in PRME Base ValueCurrent Price per PRME Share HeldPrevious Price per PRME Share Held
2025-11-11 (Tuesday)112,274USD 440,114USD 440,114
2025-11-10 (Monday)112,274PRME holding increased by 291USD 395,766PRME holding decreased by -30889USD 395,766291USD -30,889 USD 3.525 USD 3.81
2025-11-07 (Friday)111,983USD 426,655PRME holding decreased by -41434USD 426,6550USD -41,434 USD 3.81 USD 4.18
2025-11-06 (Thursday)111,983PRME holding increased by 291USD 468,089PRME holding decreased by -23356USD 468,089291USD -23,356 USD 4.18 USD 4.4
2025-11-05 (Wednesday)111,692USD 491,445PRME holding increased by 11169USD 491,4450USD 11,169 USD 4.4 USD 4.3
2025-11-04 (Tuesday)111,692PRME holding increased by 292USD 480,276PRME holding decreased by -27708USD 480,276292USD -27,708 USD 4.3 USD 4.56
2025-11-03 (Monday)111,400USD 507,984PRME holding decreased by -42332USD 507,9840USD -42,332 USD 4.56 USD 4.94
2025-10-31 (Friday)111,400USD 550,316PRME holding increased by 65726USD 550,3160USD 65,726 USD 4.94 USD 4.35
2025-10-30 (Thursday)111,400PRME holding increased by 1460USD 484,590PRME holding decreased by -14538USD 484,5901,460USD -14,538 USD 4.35 USD 4.54
2025-10-29 (Wednesday)109,940PRME holding increased by 584USD 499,128PRME holding decreased by -27968USD 499,128584USD -27,968 USD 4.54 USD 4.82
2025-10-28 (Tuesday)109,356USD 527,096PRME holding decreased by -36087USD 527,0960USD -36,087 USD 4.82 USD 5.15
2025-10-27 (Monday)109,356USD 563,183PRME holding decreased by -19684USD 563,1830USD -19,684 USD 5.15 USD 5.33
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of PRME by Blackrock for IE00BYXG2H39

Show aggregate share trades of PRME

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-10BUY2914.1103.520 3.579USD 1,041 2.97
2025-11-06BUY2914.4404.165 4.192USD 1,220 2.96
2025-11-04BUY2924.5554.270 4.298USD 1,255 2.94
2025-10-30BUY1,4604.5704.340 4.363USD 6,370 2.92
2025-10-29BUY5844.5404.810 4.783USD 2,793 2.91
2025-10-22SELL-1,1605.1105.625 5.574USD -6,465 2.85 Loss of -3,163 on sale
2025-10-20BUY5806.1806.230 6.225USD 3,611 2.81
2025-10-17BUY1,4485.4505.760 5.729USD 8,296 2.80
2025-10-15BUY2,3046.3706.650 6.622USD 15,257 2.78
2025-10-03BUY2,0376.3206.920 6.860USD 13,974 2.74
2025-10-02BUY2916.6706.700 6.697USD 1,949 2.72
2025-09-30BUY5825.5405.630 5.621USD 3,271 2.69
2025-09-26BUY5825.1205.305 5.286USD 3,077 2.66
2025-09-25BUY5825.2205.420 5.400USD 3,143 2.64
2025-09-24BUY20,6525.5605.630 5.623USD 116,126 2.63
2025-09-18BUY2345.1205.170 5.165USD 1,209 2.61
2025-09-17BUY7024.6505.040 5.001USD 3,511 2.60
2025-08-20SELL-9283.2403.320 3.312USD -3,074 2.58 Loss of -683 on sale
2025-07-30BUY9163.9204.138 4.116USD 3,770 2.54
2025-07-17SELL-4603.9004.085 4.067USD -1,871 2.43 Loss of -751 on sale
2025-07-16BUY7,0864.0404.380 4.346USD 30,796 2.42
2025-07-11SELL-1,6804.3504.610 4.584USD -7,701 2.38 Loss of -3,700 on sale
2025-07-08BUY6364.1004.130 4.127USD 2,625 2.34
2025-07-02BUY11,7153.0703.340 3.313USD 38,812 2.32
2025-06-11BUY4301.5301.670 1.656USD 712 2.36
2025-06-10BUY4301.5501.760 1.739USD 748 2.36
2025-06-04SELL-2151.3201.350 1.347USD -290 2.39 Profit of 224 on sale
2025-04-23BUY2151.7801.860 1.852USD 398 2.69
2025-04-10SELL-1,7201.1701.292 1.280USD -2,201 2.83 Profit of 2,664 on sale
2025-04-08SELL-2151.1501.420 1.393USD -299 2.87 Profit of 317 on sale
2025-04-07SELL-2151.3001.430 1.417USD -305 2.88 Profit of 316 on sale
2025-04-04SELL-1,0751.4101.540 1.527USD -1,642 2.90 Profit of 1,478 on sale
2025-04-01BUY8601.7852.110 2.077USD 1,787 2.93
2025-03-31SELL-6451.9902.000 1.999USD -1,289 2.94 Profit of 607 on sale
2025-03-14SELL-3,4561.7901.835 1.831USD -6,326 3.10 Profit of 4,378 on sale
2025-03-07SELL-4322.4002.470 2.463USD -1,064 3.18 Profit of 310 on sale
2025-03-04SELL-2162.2052.295 2.286USD -494 3.22 Profit of 203 on sale
2025-02-25BUY4322.6502.940 2.911USD 1,258 3.29
2025-02-19SELL-2163.2853.360 3.352USD -724 3.30 Loss of -10 on sale
2025-02-13BUY6482.5952.660 2.654USD 1,719 3.34
2025-02-12BUY2162.5502.565 2.564USD 554 3.36
2025-02-11BUY8602.2802.460 2.442USD 2,100 3.38
2024-12-30SELL-1,0752.7802.895 2.883USD -3,100 3.65 Profit of 829 on sale
2024-11-18SELL-3,1683.1803.385 3.364USD -10,659 4.13 Profit of 2,425 on sale
2024-11-08SELL-2114.1004.230 4.217USD -890 4.12 Loss of -21 on sale
2024-10-21SELL-2144.3704.430 4.424USD -947 0.00 Loss of -947 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of PRME

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19655,2142,2301,651,88739.7%
2025-09-18889,7612,3532,549,53234.9%
2025-09-171,096,3922,4211,951,63256.2%
2025-09-161,143,49519,0392,852,57040.1%
2025-09-15746,9751,4641,279,68858.4%
2025-09-121,022,7443921,663,30961.5%
2025-09-11510,1574401,438,47935.5%
2025-09-101,066,5576,6001,999,51253.3%
2025-09-09837,0904181,892,70144.2%
2025-09-08970,84014,4002,046,30747.4%
2025-09-05533,7832,5241,346,49739.6%
2025-09-04261,52244513,32050.9%
2025-09-03495,0261,2841,176,39442.1%
2025-09-02574,32901,307,27643.9%
2025-08-29820,3907,1721,646,89349.8%
2025-08-28372,442550970,05238.4%
2025-08-27908,82910,9211,318,49768.9%
2025-08-26326,4810779,24741.9%
2025-08-25675,1851,1401,554,24843.4%
2025-08-22745,86710,6901,537,79548.5%
2025-08-21301,8540852,17435.4%
2025-08-20794,39002,264,88335.1%
2025-08-19960,4932,4562,419,25539.7%
2025-08-18647,5121,7201,280,03750.6%
2025-08-15474,7773001,433,74433.1%
2025-08-14452,0402661,167,92538.7%
2025-08-13527,19001,764,33929.9%
2025-08-121,097,3492,1112,520,28243.5%
2025-08-111,704,7961,6612,707,38263.0%
2025-08-081,189,010103,6321,765,00367.4%
2025-08-071,934,64143,3123,398,17356.9%
2025-08-06989,6821,0071,820,50254.4%
2025-08-05951,140101,589,47159.8%
2025-08-041,373,13112,8482,704,81250.8%
2025-08-01891,816164,7992,193,55040.7%
2025-07-31934,73194,1174,072,83823.0%
2025-07-30337,9892,3931,095,62230.8%
2025-07-29482,07510,0772,556,63918.9%
2025-07-28278,84835,653916,05030.4%
2025-07-25245,59521,097829,68829.6%
2025-07-24354,0844,0421,688,81121.0%
2025-07-23496,58521,6002,794,31817.8%
2025-07-22627,6602,9601,688,99337.2%
2025-07-21710,61314,1234,358,29916.3%
2025-07-18844,0931,6943,122,88727.0%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.